A Randomized, Double-Blind Study to Compare Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of ABP 798 With Rituximab in Subjects With Moderate to Severe Rheumatoid Arthritis.
Phase of Trial: Phase III
Latest Information Update: 24 Oct 2019
Price : $35 *
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus First in man; Pharmacokinetics; Registrational
- Sponsors Amgen
- 22 Aug 2019 According to Amgen media release, this study is intended to support regulatory submissions for ABP 798.
- 24 Jan 2019 Primary endpoint (Maximum serum concentration (Cmax)) has been met, according to an Amgen media release.
- 24 Jan 2019 Primary endpoint (Area under the serum concentration-time curve (AUCinf)) has been met, according to an Amgen media release.